<DOC>
	<DOCNO>NCT01566370</DOCNO>
	<brief_summary>This randomize , double blind , placebo control trial medication zonisamide purpose reduce heavy drinking drinking , well reduce mood symptom , bipolar subject drink excessively heavily . Hypotheses : ( Primary aim ) ; Add-on zonisamide compare placebo result : 1. significant reduction heavy drinking day , drink per week per drinking day , significantly great increase abstinent day , ii ) great rate abstinence abstinence heavy drinking , great reduction biomarkers heavy alcohol use gamma-glutamyl transferase ( GGT ) , great reduction alcohol urge `` craving '' , 2 . Significant reduction prevalent mood symptom BRMS BRMeS , CARS , HAMD , worsen euthymic mood , significant improvement Clinical Global Impressions Scale-Severity . 3 . ( Secondary aim ) Add-on zonisamide compare placebo result significant reduction weight ( kilogram ) secondary weight-related metabolic factor fast glucose , lipid profile , blood pressure . 4 . ( Secondary aim ) Add-on zonisamide compare placebo result improve clinical global impression , overall functioning , quality life , reduce medical symptom . 5 . ) ( Exploratory Aims ) To examine interaction genotype medication treatment response allelic variation genetic locus relate major neurotransmitter neurophysiologic pathway relevant bipolar disorder , alcoholism , zonisamide mechanism action .</brief_summary>
	<brief_title>Zonisamide Heavy Drinkers With Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Alcoholic Intoxication</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Female/male age 1865 year Ability provide inform consent participate Presence Axis I diagnosis BD ( either type I , Type II , NOS ) , manic , hypomanic , depressive , mixed , euthymic state plus presence Axis I diagnosis current AUD and/or `` risk '' regular heavy drinking ( must average &gt; 2 heavy drinking day per week ) goal reduce stop drink treatment standard mood stabilizer medication medication know psychotropic effect mood state alcohol use ; Lithium , and/or atypical antipsychotic medication preferred medication , Subjects primary acceptable mood stabilizer describe must willing begin treatment Lithium open label fashion , English speaking , Able read eighth grade high level show evidence significant cognitive impairment ; Women childbearing potential ( i.e. , hysterectomy , bilateral oophorectomy , tubal ligation &lt; 2 year postmenopausal ) , must nonlactating , practice reliable method birth control , negative serum pregnancy test prior initiation treatment ; Must continue least 2 heavy drinking day per week ( average per month , heavy drinking define &gt; 4 standard drink per day male , &gt; 3 standard drink per day female ) screen appointment Presence another major Axis I disorder Schizophrenia Schizoaffective disorder , Delusional disorder , severe psychiatric disorder . A history suicidal violent behavior , opinion study physician , put patient significant risk suicide homicide study . Past history drug abuse dependence allow , active drug dependence ( exception nicotine dependence ) last 30 day disqualify . Serious neurological , endocrine disorder , Evidence potentially serious yet undiagnosed medical problem , Neurocognitive cognitive language limitation , incapacity providing informed consent ; Known adverse reaction zonisamide , sulfadrug allergy , penicillin allergy , severe adverse drug reaction allergy , serious systemic autoimmune illness , Patients currently undergo ECT treatment . Also patient history seizure ( febrile seizure ) , renal calculus , currently take medication could either significantly increase risk seizure ( e.g. , tricyclic antidepressant agent , Bupropion , clozaril ) , could potentially theoretically significantly influence drink behavior benzodiazepine , stimulant , opioid painkiller , sedativehypnotics , etc. ) . Subjects follow anticonvulsant medication also exclude may increase risk similar sideeffects ( similar zonisamide ) rash , cognitive impairment , potentially could confound study drink behavior ; topiramate , tiagabine , oxcarbazepine , carbamezapine , valproic acid , lamotrigine Patients , clinical examination physician , deem severely alcohol dependent permit participate outpatient level care medication trial . We , year , develop method reliably safely assess patient alcohol treatment dual diagnosis study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>alcoholism</keyword>
	<keyword>alcohol use disorder</keyword>
	<keyword>alcohol dependence</keyword>
	<keyword>alcohol abuse</keyword>
	<keyword>bipolar</keyword>
	<keyword>anticonvulsant</keyword>
	<keyword>zonisamide</keyword>
</DOC>